Syndax Pharmaceuticals, Inc. (SNDX)

19,54 -0,26 (-1,31%) Al cierre: 04:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 184

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Michael A. Metzger M.B.A.	CEO & Director	1,1M	126,68k	1971
Dr. Neil Gallagher M.D., Ph.D.	President, Head of Research & Development	720,46k	N/A	1964
Mr. Keith Alan Goldan CPA	CFO, Treasurer & Chief Accounting Officer	674,65k	N/A	1971
Mr. Luke J. Albrecht	Senior VP, General Counsel & Secretary	631,36k	387,36k	1979
Dr. Catherine Madigan M.D.	Chief Medical Officer	655,84k	N/A	1972
Dr. Peter Ordentlich B.Sc., Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	1969
Dr. Richard A. Heyman Ph.D.	Co-Founder	N/A	N/A	1957
Dr. Ronald M. Evans Ph.D.	Co-Founder, Advisor and Chair of Scientific Advisory Board	N/A	N/A	1949
Dr. Michael Downes Ph.D.	Co-Founder	N/A	N/A	N/A
Sharon Klahre	Vice President of Investor Relations & Communications	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Syndax Pharmaceuticals, Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 7; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.